Physician profile
Marcus Michael Devlin
NPI 1336338540
$2,034.38
in general payments reported to CMS, 2019-2025
12 companies · $498 in 2025
The $498 reported for 2025 was more than what 77% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $548 · 2020: $23.25 · 2021: $163 · 2022: $247 · 2023: $361 · 2024: $195 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,053.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $480.22 | 2019-2025 | Precision 1, Precision7, Clareon Panoptix Pro |
| Johnson & Johnson Vision Care, INC. | $411.34 | 2019-2025 | Acuvue |
| Coopervision INC. | $254.73 | 2019-2025 | Myday Contact Lens |
| Sun Pharmaceutical Industries INC. | $217.83 | 2021-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $138.75 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $134.66 | 2022-2025 | Infuse |
| Novartis Pharmaceuticals Corporation | $121.77 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $84.53 | 2019-2021 | |
| Visioneering Technologies, INC. | $81.59 | 2019-2020 | |
| Oyster Point Pharma, INC. | $45.91 | 2022-2023 | Tyrvaya |
| Shire North American Group INC | $38.00 | 2019 | |
| Allergan, INC. | $25.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Devlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.